Form 4: Arcutis Biotherapeutics Executive VP Sells Shares to Cover Tax Obligations

Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, Patrick Burnett, sold 2,597 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Summary

• On May 2, 2025, Patrick Burnett, Executive Vice President and Chief Medical Officer of Arcutis Biotherapeutics, sold 2,597 shares of the company's common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs) granted on February 13, 2024.
• The shares were sold at a weighted average price of $15.1877, with individual transactions ranging from $14.75 to $15.5519.
• Following the transaction, Burnett directly owns 119,339 shares of Arcutis Biotherapeutics.

Sentiment

Score: 5

Explanation: The Form 4 filing indicates a routine transaction to cover tax obligations, which is neither particularly positive nor negative.

Industry Context

Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and do not necessarily reflect a negative outlook on the company's future.

Stakeholder Impact

• The sale of shares by an executive could have a minor, temporary impact on the stock price, but is unlikely to have a significant long-term effect.

Key Dates

Keywords

Arcutis Biotherapeutics, Patrick Burnett, Form 4, Share Sale, Executive Compensation, Restricted Stock Units, Tax Withholding